Related Experiment Video
Updated: Aug 7, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate
Guillaume Grisay1, Fabio Turco2, Anna Patrikidou3
1Service d'Oncologie Médicale, CHU Helora, Haine-Saint-Paul, Belgium.
European Urology
|August 5, 2026
Abstract:
For patients with metastatic hormone-sensitive prostate cancer who achieve deep prostate-specific antigen responses with androgen deprivation therapy plus an androgen receptor pathway inhibitor, continuous treatment until progression may not be necessary. EORTC 2238 tests whether an intermittent strategy can safely reduce toxicity, improve quality of life, and lessen health care resource use.
